recreating value in specialties

STERISCIENCE | A GLOBAL SPECIALTY PLATFORM IN THE MAKING






Steriscience is an emerging sterile injectable company with a differentiated global strategy driven by strong capabilities across R&D and manufacturing and a significant focus on customer advocacy

The Company is focused on building a value-added portfolio of products that solves several challenges being faced by hospital personnel, improve hospital workflow, and ease of use

Steriscience leadership comprises the team that delivered several significant outcomes with Agila, India's first truly global specialty injectable platform (the business was sold to Mylan Inc in 2012-13 for an enterprise value of USD 1.6b, one of the largest pharma transactions in India)

Post completion of non-compete agreement with Mylan in 2020, the founders re-entered the space in 2021 with Steriscience as their version 2.0 in sterile injectables



Presenting Steriscience: a differentiated sterile injectable platform in the making



Rich Domain Experience

Led by promoters and technical team that has delivered several significant outcomes in India's first truly global injectable platform



Global Presence

Building a leading global injectables business with a presence across regulated & emerging markets



Differentiated Portfolio

Building a value-added portfolio offering of ready-to-use products that solves for challenges across stakeholders in hospitals



Strong Capabilities

Strong capabilities across R&D and Manufacturing and go-to-market



Robust Supply Chain

Significant focus on Supply chain with own manufacturing & backward integration within the group for key products



Customer centricity

Becoming a reliable supplier across customers with the highest focus on supply commitment & product quality





- Fast-track development of products by experienced in-house R&D ensures quick facility inspections & approvals
- R&D development completed for 30+ projects over 2 years including critical ready-to-use pre-filled syringe programs; 15+ ANDA filings and 20+ global filings completed



DEDICATED MANUFACTURING FOR SUPPLY RESILIENCE

- Dedicated in-house manufacturing facilities for product domains with limited suppliers and regular disruptions such as antiinfectives
- Supply security for key APIs within the group with vertical integration in Penems API ongoing to ensure cost leadership



- Converting products into ready-touse (RTU) formats to improve efficiencies in hospital workflow, safety of personnel, reduce wastages & dosing errors
- Work initiated on next phase of differentiated portfolio - first-tomarket RTU bag program in collaboration with an international R&D expert



- Infrastructure to provide end-toend services across drug development and manufacturing
- Developing/in-licensing complex products in partnership with high quality R&D organizations - inlicensed assets in the RTU space including lyo to liquid switches and other complex products including suspensions

The Steriscience Differentiators


- · Ability to identify and quickly develop a differentiated portfolio
- Carefully defined, adaptive manufacturing strategy through state-of-the-art global infrastructure
- An all-encompassing culture of quality integrated into the fabric of the organization allowing us to become a preferred partner

steriscience

Global manufacturing infrastructure – four facilities with wide-ranging capabilities across formats

- Four acquired/brownfield manufacturing sites in India, and EU
 - 1 USFDA & EU Approved sterile injectable manufacturing facility in Poland, Europe
 - 1 USFDA & EU Approved dedicated penems manufacturing facility in India, Gujarat
 - 2 USFDA approved plants in Bangalore, India one for Sterile Products & the other one dedicated Penicillin facility
- Preferred access to Industry's most modern and highly automated manufacturing site with integrated capabilities through group network

NON-POTENT INJECTABLE FACILITY IN EUROPE		DEDICATED CARBAPENEM FACILITY IN INDIA		FDA APPROVED PENICILLINS FACILITY IN INDIA		FDA APPROVED STERILE PRODUCT SITE IN INDIA	
Particulars	Features	Particulars	Features	Particulars	Features	Particulars	Features
Built-up Area	14,000 sqm	Built-up Area	100,000 sqm	Built-up Area	3,900 sqm	Built-up Area	6,500 sqm
Dosage formats	Ampoules, Lyophilized vials, Liquid vials, Pre-filled syringes	Dosage formats	Lyophilized vials, Sterile Dry Powder vials	Dosage formats	Sterile Dry powder vials	Dosage formats	Liquid - Aseptic and Terminal sterilized, Lyophilized vials, Pre-filled syringes
# employees	155	# employees	70	# employees	300+	# employees	300+
Key facility approvals	USFDA, EUGMP, GIF	Key facility approvals	USFDA, EU GMP, ANVISA, CDSCO	Key facility approvals	USFDA, EUGMP TGA, ANVISA	Key facility approvals	USFDA, EUGMP TGA, HC
Capacities	Liquid Vials – 40mn Lyophilized Vials – 2mn Pre-filled Syringes – 3mn Ampoules – 37mn	Capacities	Lyophilized Vials – 1.3mn Dry Powder Vials – 28mn	Capacities	Dry Powder Vials – 32mn	Capacities	Liquid Vials – 16mn Lyophilized Vials – 1mn Pre-filled Syringes – 10mn



A global go-to-market strategy with high focus on "partner and customer centricity"



steriscience

- **Portfolio driven GTM** strategy to achieve success across all market channels
- Marketing authorizations acquired to expedite in-market presence in US and Canada –
- □ First set of antibiotics already launched in the US in 2022
- 10+ new launches planned over the next 12 months

B2B partnerships for key emerging geographies through strong regional partners

- Capitalize on products developed and filed for regulated markets to leverage fast-track approvals
- First set of filings completed for EU/ CA/ LATAM

Carbapenem portfolio already launched in key CIS markets, India, Mexico; finalizing partnerships in Africa and SEA

Led by an experienced team with 100+ years of rich domain experience and proven track record



Neeraj Sharma 25+years CEO



CK Sundhar 25+ years Manufacturing & Projects



Biju Mathew 25+ years Quality & Tech Ops



Dr. MS Vijaykanth 20+ years R&D



Tarun Singh 15+ years Chief Financial Officer



Joe Hendrickson 25+ years Strategy and Corp Development



Murari M Mishra 15+ years CHRO



Dhriti Sethi 8+ years Head, Global BD & Portfolio

Leveraging Group infrastructure for Regulatory, Analytical, Clinical and IP services



Thank you

·

••••••